Safety and efficacy of denosumab in giant-cell tumour of bone.
Athanassios
A
Kyrgidis
Konstantinos
K
Toulis
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D000069448:Denosumab; D018212:Giant Cell Tumor of Bone / Q000188:drug therapy*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced; D010020:Osteonecrosis / Q000139:chemically induced; D053245:RANK Ligand / Q000009:adverse effects / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D053245:RANK Ligand; D000069448:Denosumab